Research-informed education, independent testing, and practical guidance across the evolving science and application of molecular hydrogen.
Explore H2HUBB articles covering molecular hydrogen research, hydrogen water, hydrogen inhalation, dosing, product testing, safety, technology, and practical education for consumers and the hydrogen industry.
/AIM: Rhupus syndrome, an overlap of rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), is a rare condition characterized by heterogeneous clinical manifestations and difficul, this case suggests molecular hydrogen therapy as a potential adjuvant for refractory Rhupus with multiple drug intolerances,…
Read ArticleIn 12 patients, every patient showed clinical improvement and excellent tolerance to H₂ therapy. These findings add human evidence supporting molecular hydrogen's therapeutic potential across the specific human…
Read ArticleIn 4 patients, erythema of these 4 patients and associated symptoms improved significantly after the H₂ treatment and did not recur. These findings add human evidence supporting molecular…
Read ArticleIn 20 patients, after 16 months of follow-up, progression-free survival of the control group was lower than that of the H₂-only group, and significantly lower than that of…
Read ArticleIn 4 patients with different doses (low and high doses) and duration (4 and 8 weeks) in patients with hyperuricemia, following an 8-week period, the High-HRW group exhibited…
Read ArticleIn 38 patients, data from the current study indicate that an H₂-enriched intravenous solution is safe for patients with acute cerebral infarction, including patients treated with t-PA. These…
Read ArticleIn 8 healthy participants, although these data suggest that inhaled hydrogen gas may be well tolerated, future studies need to be powered to further evaluate safety. These findings…
Read ArticleThis human publication evaluated hydrogen gas in 2014 patients with out-of-hospital cardiac arrest achieved spontaneous return of circulation. This pilot study suggests therapeutic potential, while larger randomized, placebo-controlled…
Read ArticleIn 50 patients with a therapeutic time window of 6 to 24 hours, the H₂ group showed no significant adverse effects with improvements in oxygen saturation. These findings…
Read ArticleIn 80 patients, all patients received 33 fractions of H₂ gas inhalation on the same day as the IMRT. These findings add human evidence supporting molecular hydrogen's therapeutic…
Read ArticleHydrogen inhalation was associated with greater reductions in systolic and diastolic blood pressure than control treatment through 24 weeks.
Read ArticleIn 2 patients, compared to the control group, participants in HI group maintained greater improvement in the level of HbA1c (-0.94% vs -0.46%), FPG (-22.7 mg/dL vs -11.7…
Read ArticleThe baseline TG value was 193.19 μL (SD = 107.44), which decreased to 151.75 μL (SD = 45.27) after 4 weeks of HRCC.
Read ArticleIn 431 patients, higher baseline HbA1c level and shorter diabetes duration is related to greater clinical response to HI. These findings add human evidence supporting molecular hydrogen's therapeutic…
Read ArticleIn 60 participants with hypertension aged 50-70 years, when stratified by age (aged 50-59 years versus aged 60-70 years), participants in the older H₂-O₂ group showed a larger…
Read Article